VYNE Therapeutics Inc. financial data

Symbol
VYNE on Nasdaq
Location
685 Route 202/206 N., Suite 301, Bridgewater, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 520 % -40.9%
Debt-to-equity 23 % +61.3%
Return On Equity -77.6 % -76.4%
Return On Assets -63.1 % -63.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.5M shares +72.7%
Common Stock, Shares, Outstanding 19.8M shares +36%
Entity Public Float 28.2M USD +115%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 42.8M shares +0.41%
Weighted Average Number of Shares Outstanding, Diluted 42.8M shares +0.41%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 476K USD -2.06%
Research and Development Expense 30.9M USD +78.3%
General and Administrative Expense 12.1M USD -13.1%
Costs and Expenses 43.1M USD +37.5%
Operating Income (Loss) -42.6M USD -38.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -38.5M USD -38.3%
Income Tax Expense (Benefit) 4K USD
Net Income (Loss) Attributable to Parent -38.5M USD -35.6%
Earnings Per Share, Basic 0 USD/shares -153%
Earnings Per Share, Diluted 0 USD/shares -153%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22M USD -25.5%
Marketable Securities, Current 17.6M USD -63.7%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD -46.9%
Assets, Current 44.3M USD -47.1%
Property, Plant and Equipment, Net 102K USD
Operating Lease, Right-of-Use Asset 32K USD -78.8%
Assets 44.7M USD -48.4%
Employee-related Liabilities, Current 819K USD +11.3%
Accrued Liabilities, Current 3.58M USD -29.4%
Liabilities, Current 5.84M USD -50.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 5.84M USD -50.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2K USD +96.6%
Retained Earnings (Accumulated Deficit) -746M USD -5.45%
Stockholders' Equity Attributable to Parent 38.9M USD -48.1%
Liabilities and Equity 44.7M USD -48.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.5M USD -43.6%
Net Cash Provided by (Used in) Financing Activities -87K USD -1640%
Net Cash Provided by (Used in) Investing Activities 19.8M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 19.8M shares +36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.28M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22M USD -25.7%
Deferred Tax Assets, Valuation Allowance 101M USD +12.1%
Deferred Tax Assets, Gross 101M USD +12.1%
Operating Lease, Liability 99K USD -53.7%
Depreciation 6K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38.5M USD -35.1%
Lessee, Operating Lease, Liability, to be Paid 101K USD -55.7%
Property, Plant and Equipment, Gross 117K USD
Operating Lease, Liability, Current 25K USD -79.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 102K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 101K USD -19.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2K USD -85.7%
Deferred Tax Assets, Operating Loss Carryforwards 75.9M USD +4.71%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 2.57M USD +4.39%
Additional Paid in Capital 784M USD +0.32%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 6K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.73M USD -20.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%